Scarica l'app Stockscreener
36.98
2.58%
0.93
Dopo l'orario di chiusura:
37.49
0.51
+1.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$36.05
Aprire:
$35.425
Volume 24 ore:
31.35M
Relative Volume:
1.12
Capitalizzazione di mercato:
$8.05B
Reddito:
$1.78B
Utile/perdita netta:
$164.40M
Rapporto P/E:
53.59
EPS:
0.69
Flusso di cassa netto:
$236.51M
1 W Prestazione:
-9.87%
1M Prestazione:
-31.54%
6M Prestazione:
-39.50%
1 anno Prestazione:
+77.36%
Intervallo 1D:
$34.93
$38.09
Intervallo di 1 settimana:
$34.93
$42.70
Portata 52W:
$19.15
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Confronta HIMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
36.98 | 8.21B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Hims & Hers Enters Direct-to-Consumer Lab Testing %%sep%% %%sitename%% - Newsweek
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing - Benzinga
Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death - The Manila Times
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and New Platform Launch - Quiver Quantitative
Why Hims & Hers Health Shares Are Sliding - TipRanks
1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds - Finviz
Hims & Hers Stock Logs 3-Day Losing Streak As Truist Calls Out Klarna GLP-1 Changes — Retail Sees Fresh Buy Zone - MSN
Hims & Hers Stock Plunge: Expansion Fails to Impress Investors - AD HOC NEWS
Hims & Hers Bets on Lab Testing to Boost Growth - The Wall Street Journal
Health Care Flat as Traders Rotate Into Sectors Less Dependent on AI Boom -- Health Care Roundup - MarketWatch
Family of WSU student files wrongful death lawsuit against Hims & Hers over antidepressant prescription - NonStop Local KHQ
Family of WSU student who died by suicide in 2023 sues Hims & Hers Health, Theta Chi fraternity for wrongful death - KREM
Key facts: Hims & Hers Health expands telehealth services; Officer sells shares - TradingView
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks - Benzinga
Family of WSU student suing telehealth company, fraternity alleging responsibility in suicide - KXLY.com
Hims & Hers Health (HIMS) Launches Labs for Preventive Care - GuruFocus
Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys - Hims Investor Relations
Hims & Hers Health Launches Lab-Testing Product - MarketScreener
Hims & Hers launches Labs for preventative care (HIMS:NYSE) - Seeking Alpha
Hims & Hers launches health monitoring service with lab testing plans - Investing.com Canada
Hims & Hers launches blood test analysis product - Sherwood News
HIMS Launches Labs for Personalized Health Insights - GuruFocus
Hims & Hers launches health monitoring service with lab testing plans By Investing.com - Investing.com South Africa
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys - The Joplin Globe
Hims & Hers Health launches lab testing with Quest DiagnosticsDJ - Investing.com
2 Strong Healthcare Stock Picks for Growth Investors - The Globe and Mail
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors - The Globe and Mail
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Boughton, Hims & Hers health CLO, sells $112k in shares - Investing.com India
Healthcare Technology Stocks Q3 Teardown: Hims & Hers Health (NYSE:HIMS) Vs The Rest - The Globe and Mail
Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants - Benzinga
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care - Yahoo Finance
How Trump’s GLP-1 move may affect telehealth companies’ fortunes - Modern Healthcare News
Is Hims & Hers Health Worth a Look After 23.9% Pullback in 2025? - Yahoo Finance
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade) (NYSE:HIMS) - Seeking Alpha
Why Hims & Hers Health (HIMS) Is Down 7.6% After Narrowing 2025 Revenue Guidance and Q3 Results - Yahoo Finance
Hims & Hers: The Profitability Squeeze Amidst Rapid Expansion - AD HOC NEWS
Hims & Hers Health’s Q3 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Hims & Hers Health's Q3 Earnings Call: Our Top 5 Analyst Questions - Finviz
Hims & Hers Health Soars on Strong Growth and Strategic Shifts - NAI500
Hers Health Inc. stock continue upward trendJuly 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? - Finviz
Hims & Hers Stock: Navigating Regulatory Headwinds and Leadership Shifts - AD HOC NEWS
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Expansion Plans - Quiver Quantitative
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care - Nasdaq
Why Analysts Say the Hims & Hers Health Story Is Shifting With New Opportunities and Risks - Yahoo Finance
How Novo Nordisk Gave Up Its Weight-Loss Gains - Bloomberg.com
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Hims & Hers Shares Tumble as Profit Miss Overshadows Revenue Growth - AD HOC NEWS
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced - Stocktwits
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.09%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):